Northrop Grumman to Participate in Baird 2017 Global Industrial Conference

FALLS CHURCH, Va., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will participate in the Baird 2017 Global Industrial Conference Wednesday, Nov. 8. Ken Bedingfield, corporate vice president and chief financial officer and Steve Movius, corporate vice president and treasurer, will present at 10 a.m. Eastern time. The presentation will be webcast live at www.northropgrumman.com.

Northrop Grumman is a leading global security company providing innovative systems, products and solutions in autonomous systems, cyber, C4ISR, strike, and logistics and modernization to customers worldwide. Please visit www.northropgrumman.com  and follow us on twitter, @NGCNews, for more information.

Note: Statements to be made at the conference, including in the presentation and in any accompanying materials, other than statements of historical fact, may constitute “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “estimate,” “guidance,” and similar expressions generally identify these forward-looking statements. These forward-looking statements speak only as of the date when made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements after the date of the subject presentation, except as required by applicable law. Forward-looking statements are not guarantees of future performance and inherently involve a wide range of risks and uncertainties that are difficult to predict. A discussion of these risks and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission.

Contact:

Tim Paynter (Media)703-280-2720 (office)[email protected] 

Steve Movius (Investors)703-280-4575[email protected] 

You May Also Be Interested In

• Andersen closes secondary offering of 4.9M shares at $44 each
• Northrop Grumman (NOC) Declares $2.47 Quarterly Dividend; 1.7% Yield
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall